Program

Falk Symposium 191

Liver Diseases in 2013: Advances inPathogenesis and Treatment

October 4 – 5, 2013Park Plaza Westminster BridgeLondon, Great Britain

CME credits12

Awardedwith

3

Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

List of Speakers, Moderatorsand Scientific Organizers . . . . . . . . . . . . . . . . . . . . . 20

Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

12 credit hours (CME) have been awarded for the Falk Symposium 191 by the EuropeanUnion of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG) .

4

Preface

I am writing on behalf of the Scientific Organising Committee to invite you to attend theforthcoming Falk Symposium to be held in London on the 4th and 5th October, 2013 .The topic of the meeting is “Liver Diseases in 2013: Advances in Pathogenesis andTreatment” .

In keeping with the many previous successful symposia in the fields of Gastroenterologyand Hepatology organised by the Falk Foundation, we have arranged a programme aimedat combining “cutting edge” basic science with the latest clinical advances in the managementof common liver diseases to be delivered by internationally recognised experts . Interactivecase presentations with audience participation will also form an important part of theprogramme .

We are also encouraging young ,aspiring hepatologists to attend through poster presentationsand travel grants for successful applicants . We hope that you will be able to come to Londonin 2013, home of the 2012 Olympic Games and make another truly international meetingequally successful!

We look forward to seeing you in London .

Sincerely yours,

On behalf of the scientific organizersRoger W . Chapman, Oxford

Falk Symposium 191

Liver Diseases in 2013: Advances inPathogenesis and Treatment

Park Plaza Westminster BridgeLondon, Great Britain

5

Registration:Thursday, October 3, 20138 .00 – 18 .00 hat the congress office

Scientific Organization:R . W . Chapman, Oxford (Great Britain)D . H . Adams, Birmingham (Great Britain)U . Beuers, Amsterdam (The Netherlands)C . P . Day, Newcastle-Upon-Tyne (Great Britain)M . P . Manns, Hannover (Germany)

Congress Venue:Park Plaza Westminster Bridge200 Westminster Bridge RoadLondon SE1 7UTGreat Britain

Information:Dr . Roger William ChapmanJohn Radcliffe HospitalNHS TrustDepartment of GastroenterologyHeadley Way HeadingtonOxford OX3 9DUGreat BritainTelephone: +44(0)186/5220618Telefax: +44(0)186/5751100E-Mail: roger .chapman@ndm .ox .ac .uk

Official Language:English

Posters:For details see page 10 .

6

Friday, October 4, 2013

8.20 Welcome and Opening R . W . Chapman,Oxford

Session IFrom bench to bedside in hepatologyChair: D . H . Adams, Birmingham; A . Sanchez-Fueyo, London

8.30 The therapeutic potential of stem cells in liver disease P . Newsome,Birmingham

8.50 Cellular therapy to modulate autoimmune liver A . W . Lohse,disease Hamburg

9.10 The inflammasome in liver injury and NAFLD W . Z . Mehal,New Haven

9.30 Immune signatures as biomarkers of tolerance A . Sanchez-Fueyo,and immune activation London

9.50 Purinergic signaling in liver disease S . C . Robson,Boston

10.10 Platelets: Novel anti-inflammatory targets in L . G . Guidotti,immune-mediated liver disease Milan

10.30 Coffee break with poster session

Session IIViral hepatitis IChair: G . J . Alexander, Cambridge; M . Pinzani, London

11.00 Role of the innate and adaptive immune system M . Maini,in viral hepatitis London

11.30 The HCV life cycle: In vitro tissue culture systems T . Pietschmann,and therapeutic targets Hannover

11.50 The role of molecular HCV diagnostics in the M . R . Thursz,management of chronic hepatitis C London

12.10 Viral hepatitis and liver transplantation – Pathogenesis, X . Forns,prevention and therapy of recurrent disease Barcelona

12.30 Case presentation M . Shah,Cambridge

13.00 Lunch break with poster session

7

Friday, October 4, 2013

Session IIIViral hepatitis IIChair: G . M . Dusheiko, London; H . C . Thomas, London

14.00 Long-term results in HBV therapy: HBsAg P . Marcellin,loss/seroconversion and histology Clichy

14.30 Biomarkers for current and future HBV therapies M . Cornberg,Hannover

14.50 Interferonfree treatments for chronic hepatitis C G . M . Dusheiko,London

15.10 Case presentation G . M . Dusheiko,London

15.30 Coffee break with poster session

Session IVHepatobiliary tumorsChair: H . Reeves, Newcastle-Upon-Tyne; G . J . Gores, Rochester

16.00 The pathogenesis of hepatocellular carcinoma A . Vogel,Hannover

16.25 Treatment of hepatocellular carcinoma: J . Bruix,State-of-the-Art Barcelona

16.50 The pathogenesis biliary tract cancer G . J . Gores,Rochester

17.15 Update on the management of cholangiocarcinoma S . P . Pereira,London

17.35 Case presentation J . Dyson,Newcastle-Upon-Tyne

8

Saturday, October 5 , 2013Session VFatty liver diseasesChair: C . P . Day, Newcastle-Upon-Tyne; M . Pinzani, London

8.30 Mechanisms of disease A . E . Feldstein,La Jolla

9.00 Diagnosis and investigation V . Ratziu,Paris

9.20 NASH Natural history and HCC S . H . Caldwell,Charlottesville

10.00 Treatment of NASH C . P . Day,Newcastle-Upon-Tyne

10.20 Case presentation Q . M . Anstee,Newcastle-Upon-Tyne

10.30 Coffee break with poster session

Session VIWhat’s hot in hepatologyChair: M . P . Manns, Hannover; M . R . Thursz, London

11.00 IgG4-associated cholangitis U . Beuers,Amsterdam

11.20 Developing vaccines against hepatitis C virus E . Barnes,Oxford

11.40 Coagulopathy in liver disease, complication or therapy? E . Villa,Modena

12.00 Cell based therapy for alpha one anti trypsin S . T . Rashid,deficiency and inherited liver diseases Cambridge

12.20 Presentation of poster prizes R . W . Chapman,Oxford

12.30 Lunch with poster session

9

Saturday, October 5 , 2013Session VIIAutoimmune liver diseasesChair: U . Beuers, Amsterdam; R . W . Chapman, Oxford

13.30 Genetics of autoimmune liver disease G . Hirschfield,Birmingham

13.50 Pathogenesis and ‘State-of-the-Art’ treatment of AIH M . P . Manns,Hannover

14.15 Pathogenesis of PBC and PBC-associated fatigue D . E . J . Jones,Newcastle-Upon-Tyne

14.35 Evidence-based treatment of primary biliary cirrhosis R . Poupon,(PBC) Paris

14.55 Coffee break with poster session

15.15 Immunopathogenesis of PSC D . H . Adams,Birmingham

15.35 Therapeutic role of bile salts and nuclear receptor M . Trauner,agonists in fibrosing cholangiopathies Vienna

15.55 Pathogenesis and treatment of pruritus in cholestasis A . E . Kremer,Erlangen

16.15 Case presentation K . Williamson,Oxford

16.50 Concluding remarks M . P . Manns,Hannover

10

Poster SessionPosters will be exhibited on October 4 – 5, 2013, at the “Park Plaza Westminster Bridge“,London . The authors will be in attendance during coffee and lunch breaks on both days .

1 . Evaluation of serum nitric oxide before and after local radiofrequency thermalablation for hepatocellular carcinomaH . Abd el Moety, A . Abd el Moety, P . Salem (Alexandria, EG)

2 . Adiponectin a differential marker between steatosis and steatohepatitisH . Abd el Moety, D . Maharem, M . El Gandour, A . Abd el Moety (Alexandria, EG)

3 . Evaluation of nitric oxide as a novel diagnostic marker for hepatocellularcarcinomaH . Abd el Moety, A . Abd el Moety (Alexandria, EG)

4 .* Decompensated alcoholic liver disease (ALD): High long-term mortality despiteinitial survivalA . Al-Joudeh, E . McFarlane, M . Karajeh, D . Gleeson (Rotherham, SouthYorkshire, Sheffield, GB)

5 .* Glucagon-like peptide-1 analogue, liraglutide, reduces adipose insulin resistanceand hepatic de novo lipogenesis in nonalcoholic steatohepatitis: Sub-studyresults of a phase II randomised-control clinical trialM .J . Armstrong, D . Hull, K . Guo, D . Barton, J .M . Hazlehurst, J . Yu,J .W . Tomlinson, P .N . Newsome (Birmingham, GB)

6 . Comparative study of the efficacy of rifaximin in comparison with lactulose forthe treatment of hepatic encephalopathyF . Asal, A .K . Tawfik, R . Salah, S . Mansour, A .H . Abed-El Hameed,M . El-Hamamsy (Tanta, Cairo, EG)

7 . Frequency and predictive factors of granulomatous hepatitis in patients withperitoneal tuberculosisN . Ben Mustapha, A . Labidi, M . Serghini, M . Fekih, J . Boubaker, A . Filali (Tunis,TN)

8 . Analysis of polymorphisms of BER genes (hOGG1, XRCC1) in HCC patientsJ . Bialkowska, M . Jablkowski, J . Szemraj (Lodz, PL)

9 . Rat hepatocytes isolated from fatty liver are more sensitive to tert-butylhydroperoxide-induced oxidative stressZ . Cervinkova, O . Kucera, H . Lotkova, T . Garnol, R . Endlicher (Hradec Kralove,CZ)

11

10 . Intraoperative platelet transfusion is associated with poor graft and overallsurvival in liver transplantationJ .L . Chin, S . Hanis Hishamuddin, A . O‘Sullivan, P .A . McCormick (Dublin, IE)

11 . Can spleen stiffness reflect changes in portal pressure after liver transplantation?J .L . Chin, G . Chan, J .D . Ryan, P .A . McCormick (Dublin, IE)

12 .* Large volume paracentesis (LVP) can be safely performed by junior doctorswithout ultrasound guidanceB . Conduit, E . Wesley, J . Christie, U . Thalheimer (Exeter, GB)

13 . Renal impairment occurs after large volume paracentesis (LVP) in patients withcirrhosis despite adequate albumin administrationB . Conduit, E . Wesley, J . Christie, U . Thalheimer (Exeter, GB)

14 .* Can weight loss and exercise improve NAFLD?I . Copaci, L . Micu, E . Caceaune, G . Chiriac, G . Ismail (Bucharest, RO)

15 . Alternative treatments for hepato-renal syndrome in patients with cirrhosisI . Copaci, G . Chiriac, L . Micu, E . Mindrut (Bucharest, RO)

16 . Long term entecavir treatment, for nucleotide naive, non-cirrhotic, hepatitis BHBsAg (+) and eAG (+) field patients in the northwest of GreeceK .J . Dabos, N . Akritidis, M . Papadopoulos (Edinburgh, GB; Ioannina, GR)

17 . Vitamin D status in Mongolian patients with HCVY . Dahgwahdorj, D . Tungalag, N . Otgon, D . Bekhbold (Ulaanbaatar, MN)

18 . The effect of HBV infection on liver metastases of colorectal cancerC . Deliu, E .F . Georgescu, M . Bezna, R . Teodorescu (Craiova, RO)

19 . Chronic hepatitis B virus infection – Clinical, laboratory, serological andhistologic characteristicC . Deliu, E .F . Georgescu, D . Neagoe, C . Hoanca, R . Teodorescu, M . Bezna(Craiova, RO)

20 . Combined treatment of a carcinoma of the stomach with metastases in a liverM . Djuraev, A .Yusupbekov, A . Dosov (Tashkent, UZ)

21 . Diagnostic difficulties, therapeutic strategies and performance of scoringsystems in patients with autoimmune hepatitis and concurrent hepatitis B/CC . Efe, S . Wahlin, E . Ozaslan, T . Purnak, L . Muratori, C . Quarneti, G . Tatar,H . Simsek,P . Muratori, T . Schiano (Ankara, TR; Stockholm, SE; Bologna, IT; New York, US)

12

22 .* Novel redox nanoparticles reduce oxidative stress and improve fibrosis in NASHmouse modelA . Eguchi, T . Yoshitomi, C . Johnson, A . Wree, Y . Nagasaki, A .E . Feldstein(La Jolla, US; Tsukuba, JP)

23 .* The balance between T helper 17 and FOXP3+ T regulatroy cells in patients withchronic hepatitis C: Relation to disease activity and hepatic fibrosisH . El Aggan, N . Farahat, L . Younis, A . ElYamany (Alexandria, EG)

24 . Can rapid virological response predict sustained virological response in naiveEgyptian patients with HCV genotype 4 treated by peginterferon plus ribavirin?M . El-Hamamsy, H . Elbatae, K . Mohie-Edeen (Cairo, Tanta, EG)

25 .* Transient elastography is a useful clinical tool to predict the presence of minimalhepatic encephalopathy in a cohort of compensated cirrhotic patientsZ . Galvin, M .-T . O‘Neill, D . Lowry, S . Stewart (Dublin, IE)

26 . Review of hospital patients with ALT > 1000 IU/LZ . Galvin, A . McDonough, J . Ryan, M .-T . O‘Neill, S . Stewart (Dublin, IE)

27 . Diagnostic approach in Wilson disease using ceruloplasmin and urinary copperexcretion according to Leipzig scoring systemD . Gancheva, M . Atanassova, M . Stamboliyska, I . Kotzev, M . Kaneva (Varna, BG)

28 . TGFβ1 stimulation of human bone marrow mesenchymal stem cells (MSC)enhances their hepatic engraftment and therapeutic effect in injured liver viaupregulation of CXCR3 functionA . Garg, N .J . Davies, V . Aldridge, A .L . King, S .T . Ward, K . Li, R . Bernstein,S . Desai, J . Fear, P .F . Lalor, P .N . Newsome (Birmingham, GB)

29 . Five year clinical review of 78 cases of hepatocellular carcinomZ . Gashi, S . Zekaj, A . Haziri (Prishtina, KOS)

30 . The safety and tolerability of the budesonide in treatment of autoimmunehepatitisA . Genunche-Dumitrescu, D . Badea, M . Badea, P . Mitrut, A . Badea (Craiova, RO)

31 . Therapeutic options in the treatment of nonalcoholic steatohepatitis in obesepatientsA . Genunche-Dumitrescu, D . Badea, M . Badea, P . Mitrut, D . Neagoe, A . Badea,D . Duta (Craiova, RO)

13

32 .* Prevalence, virological and clinical characteristics of chronic hepatitis Delta (CHD)in RomaniaL .S . Gheorghe, I . Csiki, S . Iacob, R . Cerban, A . Trifan, M . Grigorescu, A . Motoc,A . Suceveanu, F . Caruntu, I . Sporea, C . Rogoveanu, A . Alexandrescu(Bucharest, Iasi, Cluj-Napoca, Timisoara, RO)

33 . Relationship between selectins and histologic changes in chronic viral liverdiseasesG .I . Gilyazova, A .V . Yagoda, P .V . Koroy (Stavropol, RU)

34 .*Decompensated alcoholic liver disease (ALD) is associated with starting heavydrinking at an older age: A case-control studyD .C . Gleeson, A . Ali, J . Jones, M .P . Bradley, R .J . Peck, K . McCormack (Sheffield,GB)

35 . Pregnancy in biliary atresia; Transient post-delivery hypoalbuminemia withmassive ascitesE . Granot, Z . Cohen, A . Ben-Arie, S . Yagel (Rehovot, Beer-Sheva, Jerusalem, IL)

36 . Prevalence of falls in the UK primary biliary cirrhosis populationL . Griffiths, D . Jones, J . Newton (Newcastle upon Tyne, GB)

37 . Expression analysis of zinc transporters in human peripheral blood immune cellsK . Grüngreiff, T . Wex, K . Schütte, M . Stengritt, D . Reinhold (Magdeburg, DE)

38 . Primary sclerosing cholangitis in the course of inflammatory bowel disease inchildrenU . Grzybowska-Chlebowczyk, S . Wiecek, M . Kajor, U . Chlebowczyk, H . Wos(Katowice, PL)

39 . The seroprevelance of both hepatitis B and hepatitis C at the first step healthorganizations and the difference between the ruban and rural areasF . Kalem, S . Yüksekkaya, M . Basaranoglu (Ankara, TR)

40 . Alkaline phosphatase – The next independent predictor of the poor 90-dayoutcome in alcoholic hepatitisB . Kasztelan-Szczerbinska, M . Slomka, K . Celinski, M . Szczerbinski (Lublin, PL)

41 . Gender-related alterations of inflammatory response in patients with alcoholicliver diseaseB . Kasztelan-Szczerbinska, A . Surdacka, M . Slomka, J . Rolinski, K . Celinski,M . Szczerbinski (Lublin, PL)

14

42 . The Treg/Th17 lymphocyte imbalance in patients with alcoholic liver diseaseB . Kasztelan-Szczerbinska, A . Surdacka, M . Slomka, J . Rolinski, K . Celinski,M . Szczerbinski (Lublin, PL)

43 . Association of serum adiponectin, leptin and resistin concentrations with theseverity of liver dysfunction and the disease complications in alcoholic liverdiseaseB . Kasztelan-Szczerbinska, A . Surdacka, M . Slomka, J . Rolinski, K . Celinski,M . Szczerbinski (Lublin, PL)

44 . Treatment peculiarities of nonalcoholic steatohepatitis in patients with diabetesmellitusN . Kharchenko, G . Anokhina, V . Kharchenko, D . Janelidze (Kiev, UA)

45 . New approaches to the correction of lipid exchange disorders in patients withmetabolic syndromV . Kharchenko, I . Korulya, D . Janelidze (Kiev, UA)

46 .*Pioglitazone improves virological response to peginterferon alpha-2b/ribavirincombination therapy in hepatitis C genotype 4 patients with insulin resistanceM . Khattab, M . Emad, A . Abdelaleem, M . Eslam, R . Atef, Y . Shaker, L . Hamdy,M . Sharaf-Eldin (Tanta, EG)

47 .* FTY720 increases the hepatic retention of purified haematopoietic stem cells inchronic liver injury resulting in an enhanced anti-fibrotic actionA . King, D . Houlihan, D . Kavanagh, S . Suresh, A . Garg, H . Sumption,J . Frampton, D . Adams, P .N . Newsome (Birmingham, GB)

48 . The ratios of pro to anticoagulant factors: Index of hemostatic imbalance incirrhotic patientsA . Laabidi, H . Baccouche, M . Fekih, N . Ben Mustapha, S . Mahjoub,N . Ben Romdhane, A . Filali (Tunis, TN)

49 . Thrombotic risk factors in cirrhotic patientsA . Laabidi, H . Baccouche, H . Kaabi, S . Mahjoub, M . Fekih, S . Hamida, A . Filali,N . Ben Romdhane (Tunis, TN)

50 . Prolonged entecavir therapy is not effective for HBeAg seroconversion intreatment-naive chronic hepatitis B patients with a partial virological responseH .W . Lee, D .G . Ahn, H .J . Kim (Seoul, KR)

51 .* Preoperative TACE improves the survival in the resectable HCC with highlyelevated AFPJ .M . Lee, D .S . Song, K .-M . Lee, W .C . Chung, Y .W . Lee, Y .Y . Chung, Y .S . Oh,H .J . Sung (Suwon, Gyeonggi-do, KR)

15

52 . Outcomes of surgical resection following downstaging the unresectablehepatocellular carcinoma with combination treatmentsK .-M . Lee, D .S . Song, W .C . Chung, D .B . Kim, S .J . Lee, J .M . Lee (Suwon,Gyeonggi-do, KR)

53 .* Carriage of PNPLA3 I148M is associated with an increased risk of non-alcoholicfatty liver disease associated hepatocellular carcinomaY .-L . Liu, G .L . Patman, J . Leathart, A .D . Burt, A .-C . Piguet, J .-F . Dufour, C .P . Day,A .K . Daly, H . Reeves, Q .M . Anstee (Newcastle upon Tyne, GB; Bern, CH)

54 . Role of SLC22A1 gene in the response of hepatocellular carcinoma andcholangiocarcinoma to sorafenibR .I .R . Macias, L . Sanchez-Vicente, E . Herraez, O . Briz, E . Lozano, J . Vaquero,A .G . Blazquez, M .A . Serrano, L . Bujanda, J . Banales, J .J .G . Marin (Salamanca,San Sebastian, ES)

55 . Do endosonography findings predict variceal recurrence after endoscopic bandligation?L . Masalaite, J . Valantinas, J . Stanaitis (Vilnius, LT)

56 . Liver tumors – The vascularisation pattern assessed by contrast-enhancedultrasoundC . Mihai, A . Blaj, M . Badea, O . Jigaranu, C . Cijevschi Prelipcean (Iasi, RO)

57 . PNPLA3 rs738409 polymorphism and the possible involvement in developmentof NAFLDD . Neagoe, A . Amzolini, G . Ianosi, M . Ioana, F . Burada, A . Farmazon, T . Ciurea(Craiova, RO)

58 . The relationship between non-invasive evaluation of fibrosis (by transientelastography) and genes polymorphism in NAFLDD . Neagoe, G . Ianosi, A . Amzolini, M . Ioana, F . Burada, A . Farmazon, T . Ciurea(Craiova, RO)

59 . Developing ImageStreamX as a sensitive and clinically relevant tool for detectionfor circulating tumour cells (CTCs) in patients with hepatocellular cancer (HCC)L . Ogle, D . Jamieson, N . Curtin, A . Boddy, R . Plummer, H . Reeves (Newcastleupon Tyne, GB)

60 . Differential STAT3 expression in PBMCS from HCV genotype 1 & 3 infectedpatients may explain lack of responsiveness to IFN-α therapyM .-T . O‘Neill, N . Stevenson, Z . Galvin, S . Stewart, C . O‘Farrelly (Dublin, IE)

16

61 . Expansion of arginase-expressing myeloid-derived suppressor cells in chronichepatitis B virus infectionL .J . Pallett, M . Hanifa, N . Davies, M . Jover Cobos, A . Schurich, A . Das, R . Gilson,A . Bertoletti, M .K . Maini (London, GB; Singapore, SG)

62 . Presence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) in cirrhosisP Possible hint towards the involvement of gut mucosal immune system?M . Papp, N . Sipeki, Z . Vitalis, T . Tornai, I . Altorjay, I . Tornai, M . Udvardy,K . Fechner, B . Teegen, S . Jacobsen, A . Sumegi, G . Veres, P . L . Lakatos,J . Kappelmayer,P .L . Antal-Szalmas (Budapest, Debrecen, HU; Lübeck, DE)

63 . IL28B CC and IL 10R-1087 GG genotypes are protective for chronic genotype 1HCV infection in an East-central european countryA . Pár, G . Par, I . Tornai, F . Szalay, D . Varszegi, E . Frater, M . Papp, G . Lengyel,J . Feher, M . Varga, J . Garvain, J . Schuller, Z . Nemes, Z . Peterfi, A . Tusnadi,B . Hunyady, A . Haragh, Z . Szinku, A . Vincze, P . Kisfali, B . Melegh(Pecs, Debrecen, Budapest, Bekescsaba, Szekesfehervar, Szolnok,Kaposvar, HU)

64 . IL28B CC genotype is associated with increased Th1 but not Th2 type cytokineproduction by peripheral blood mononuclear cells in chronic HCV1 infectionG . Par, T . Berki, L . Palinkas, L . Szereday, B . Hunyady, A . Vincze, A . Par, B . Melegh(Pecs, HU)

65 . Liver stiffness measurement predicts the presence of large oesophageal varicesin patients with chronic liver diseasesG . Par, A . Trosits, F . Pakodi, I . Szabo, J . Czimmer, A . Illes , S . Godi, J . Bajor,P . Sarlos, P . Kenyeres, A . Vincze, A . Par (Pecs, HU)

66 . Outcomes after ileal pouch anal anastomosis in patients with primary sclerosingcholangitisM . Pavlides, M . Rahman, J . Cleland, R . Gaunt, S . Travis, N . Mortensen,R .W . Chapman (Oxford, GB)

67 .* Success rate of re-attempted ERCP after failed initial precut shpincterotomy forbiliary cannulationM . Pavlides, A . Barnabas, N . Fernandopulle, A .A . Bailey, J . Collier,J . Philips-Hughes, A . Ellis, R .W . Chapman, B . Braden (Oxford, GB)

68 . The effect of hyperhomocysteinemia and associated metabolic disturbances onthe liver fibrosis in patients with chronic hepatitisN . Pentyuk, N . Kharchenko, I . Lopukh, D . Janelidze (Vinnitsa, Kiev, UA)

17

69 . The strong expression of PRL-3 protein in liver metastases of colorectal cancerA . Pryczynicz, K . Niewiarowska, K . Guzinska-Ustymowicz, W . Famulski,V . Dymicka-Piekarska, H . Car, A . Borsuk, M . Hawryluk, A . Kemona(Bialystok, PL)

70 . Polymorphism of tumor necrosis factor –α-238 G/A is associated withprogression of non alcoholic fatty liver disease: A study in Dr . Kariadi HospitalSemarang IndonesiaH .D . Purnomo, F .E .P . Mundhofir, Hirlan, Kasno, E . Sudijanto, Darmono,Daldiyono, R . Djokomoeljanto, S .M .H . Faradz (Semarang, ID)

71 . Detecting of advanced fibrosis among patients with biopsy-proven with NAFLDwith non-invasive testsS . Raicevic Sibinovic, A . Nagorni, M . Radisavljevic, V . Brzacki (Nis, RS)

72 .* Inhibition of PECAM-1 by Plasminogen K1-5 not only inhibits orthotopichepatoma growth but also prevents ascitesE . Raskopf, C .P . Strassburg, T . Sauerbruch, V . Schmitz (Bonn, DE)

73 . Real world experience of rifaximin in hepatic encephalopathyJ . Roche, T . Heron, E . Henry, J .F . Dillon (Dundee, GB)

74 . Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virusreplicationI .A . Rowe, S .K . Galsinh, G .K . Wilson, R . Parker, S . Durant, C . Lazar, N . Branza-Nichita, R . Bichnell, D .H . Adams, P . Balfe, J .A . McKeating (Birmingham, GB;Bucharest, RO)

75 . High-throughput MALDI-TOF MS as an alternative approach to HBV genotypingM . Rybicka, P . Stalke, M . Dreczewski, T . Smiatacz, K .P . Bielawski (Danzig, PL)

76 . Role of FXR in controlling the expression of genes involved in the lack ofresponse of liver cancer to chemotherapyL . Sanchez-Vicente, R .I .R . Macias, J . Vaquero, O . Briz, E . Herraez, E . Gonzalez-Sanchez, M .J . Perez, M .R . Romero, M .J . Monte, J . Muntané, J .J .G . Marin(Salamanca, Sevilla, ES)

77 .* The cellular mechanism of isoniazid and rifampicin induced hepatocytes injury incytochrome P450 2E1 over expressing cellsA . Santra, D . Bishnu, S . Santra, G .K . Dhali, A . Chowdhury (Kolkata, IN)

78 . Hepatic stellate cells activation through phagocytosis of isoniazid inducednecrotic hepatocytes: An in-vitro studyS . Santra, D . Bishnu, G .K . Dhali, A . Chowdhury, A . Santra (Kolkata, IN)

18

79 . Hypocholesterolemia is accompanied by low level of intracellular cholesterol inPBMCs of CHC patientsM . Sidorkiewicz, B . Jozwiak, M . Grek, A . Piekarska (Lodz, PL)

80 . IL-28 polymorphism and iron homeostasis disturbances in chronic hepatitis C:Preliminary polish single center studyK . Sikorska, A . Szpitter, A . Bernat, P . Stalke, T . Smiatacz, M . Gajewski,K .P . Bielawski (Danzig, PL)

81 . Non-alcoholic fatty liver disease: Risk factors and frequency assessmentN . Silivontchik, V . Goloborodko, A . Lednik, I . Kachar, D . Odinets, I . Patorskaya,L . Plotnikova, E . Voronko, L . Bogush, O . Zhigaltsova (Minsk, BY)

82 . Outreach service – Fostering equity and access for liver transplantationR . Sinha, J .L . Hulley, S . White, A . Douglass, S . Masson(Cleveland, Middlesborough, Newcastle upon Tyne, GB)

83 .*Sulfatase-2 (SULF2) – A therapeutic candidate in patients with hepatocellularcancer (HCC)?R . Sinha, L . Ogle, R . Harrison, A . Herriot, G . Patman, G . Beale, D . Televantou,F . Oakley, H . Reeves (Cleveland, Newcastle upon Tyne, GB)

84 . Low expression of hepcidin in liver tissue is not associated with an effect oftreatment with pegylated interferon and ribavirin of chronic hepatitis C:A preliminary studyP . Stalke, K . Sikorska, T . Romanowski, E . Izycka-Swieszewska, K .P . Bielawski(Danzig, PL)

85 .* Serum levels of angiogenesis-related biomarkers in patients with alcoholic liverdisease: Their association with liver disease complications and outcomeM . Szczerbinski, B . Kasztelan-Szczerbinska, A . Surdacka, M . Slomka, J . Rolinski,K . Celinski (Lublin, PL)

86 . Comparison of autoimmune hepatitis patients‘ characteristics in non-Caucasianand Caucasian ethnic groupsN .N . Than, J . Mann, J . Hodson, P . Nightingale, D .H . Adams, Y .H . Oo(Birmingham, Leeds, GB)

87 . Optimising tools to stratify outcome in primary biliary cirrhosis: AST/platelet ratioindex predicts clinical outcome independent of UDCA responseP . Trivedi, T . Bruns, K .-K . Li, H . Shah, D . Tripathi, J . Neuberger, G .M . Hirschfield(Birmingham, GB)

19

88 .*VAP-1 activity is elevated in PSC and modulates a α4β7-dependent lymphocyteadhesion to HSEC under flowP . Trivedi, C . Weston, C . Corbett, E . Liaskou, D . Adams (Birmingham, GB)

89 . Impact of proton pump inhibitor (PPI) use on clinical course of cirrhosisZ . Vitalis, M . Papp (Debrecen, HU)

90 .*CD8αα expression, activation and terminal differentiation are shared features ofthe bulk CD8+ T-cell populations in chronic hepatitis B and HIV-1 infectionsL .J . Walker, E . Marrinan, M . Münchhoff, J . Ferguson, H . Kloverpris, H . Cheroutre,E . Barnes, P . Goulder, P . Klenerman (Newcastle upon Tyne, Oxford, GB; Durban,ZA; San Diego, US)

* = Posters of Distinction

20

List of Speakers, Moderators and Scientific Organizers

Prof. Dr. David H. AdamsQueen Elizabeth HospitalInstitute of Clinical SciencesLiver Research LaboratoriesBirmingham B15 2THGreat Britaind .h .adams@bham .ac .uk

Dr. Graeme J. AlexanderConsultant HepatologistAddenbrooke‘s HospitalHills RoadCambridge CB2 2QQGreat Britaingja1000@doctors .org

Dr. Quentin M. AnsteeUniversity of NewcastleThe Medical SchoolInstitute of Cellular Medicine3rd Floor, William Leech Bldg .Framlington PlaceNewcastle-Upon-Tyne NE2 4HHGreat Britainquentin .anstee@ncl .ac .uk

Dr. Ellie BarnesUniversity of OxfordPeter Medawar Bldg .Pathogen ResearchSouth Parks RoadOxford OX1 3SYGreat Britainellie .barnes@ndm .ox .ac .uk

Prof. Dr. Ulrich BeuersUniv . van Amsterdam, Tytgat Inst .for Liver & Intestinal ResearchDepartment of Gastroenterology& Hepatology, B1-244 .2Meibergdreef 91105 AZ AmsterdamThe Netherlandsu .h .beuers@amc .uva .nl

Prof. Dr. Jordi BruixHospital Clinico y ProvincialUniversidad de BarcelonaBCLC GroupLiver Unitc/ Villarroel no . 17008036 BarcelonaSpainjbruix@clinic .ub .es

Stephen H. Caldwell, M.D.Professor of MedicineUniversity of VirginiaSchool of MedicineGI & Hepatology DivisionHospital West, P .O . Box 800708Charlottesville VA 22908USAshc5c@virginia .edu

Dr. Roger W. ChapmanJohn Radcliffe HospitalNHS TrustDepartment of GastroenterologyHeadley Way HeadingtonOxford OX3 9DUGreat Britainroger .chapman@ndm .ox .ac .uk

PD Dr. Markus CornbergKlinik für Gastroenterologie,Hepatologie und EndokrinologieMedizinische Hochschule HannoverCarl-Neuberg-Str . 130625 HannoverGermanycornberg .markus@mh-hannover .de

Prof. Dr. Christopher P. DayUniversity of NewcastleThe Medical SchoolCenter for Liver ResearchWilliam Leech BuildingFramlington PlaceNewcastle-Upon-Tyne NE2 4HHGreat Britainc .p .day@ncl .ac .uk

21

Dr. Geoffrey M. DusheikoRoyal Free HospitalSchool of MedicineAcademic Dept . of MedicineRowland Hill StreetLondon NW3 2PFGreat Britaing .dusheiko@ucl .ac .uk

Dr. Jessica DysonFreeman HospitalLiver UnitHigh HeatonNewcastle-Upon-Tyne NE7 7DNGreat Britainjessicadyson@doctors .org .uk

Ariel E. Feldstein, M.D.Professor of PediatricsUCSD School of MedicineDivision of Pediatric Gastroentorology,Hepatology and Nutrition9500 Gilman DriveLa Jolla CA 92093USAafeldstein@ucsd .edu

Dr. Xavier FornsHospital Clinic of BarcelonaLiver UnitCarrer de Villarroel 17008036 BarcelonaSpainxforns@clinic .ub .es

Gregory J. Gores, M.D.Professor of MedicineMayo ClinicDivision of Gastroenterologyand Hepatology200 First Street SWRochester MN 55905USAgores .gregory@mayo .edu

Prof. Dr. Luca G. GuidottiSan Raffaele Scientific Inst .DIBITVia Olgettina n . 5820132 MilanoItalyguidotti .luca@hsr .it

Dr. Gideon HirschfieldUniversity of BirminghamCenter of Liver ResearchInstitute of Biomedical Research5th Floor, Room 543Birmingham B15 2TTGreat Britaing .hirschfield@bham .ac .uk

Prof. Dr. David E. J. JonesUniversity of NewcastleThe Medical SchoolCenter for Liver ResearchFloor 4, William Leech BuildingFramlington PlaceNewcastle-Upon-Tyne NE2 4HHGreat Britaindavid .jones@newcastle .ac .uk

Dr. Andreas E. KremerMedizinische Klinik IUniversitätsklinikumErlangen-NürnbergUlmenweg 1891054 ErlangenGermanyandreas .kremer@uk-erlangen .de

Prof. Dr. Ansgar W. LohseMedizinische Klinik IUniversitätsklinikum EppendorfMartinistr . 5220246 HamburgGermanyalohse@uke .de

Prof. Dr. Mala MainiResearch Department of ImmunologyUniversity College LondonRayne Institute5 University StreetLondon, WC1E 6JFGreat Britainm .maini@ucl .ac .uk

22

Prof. Dr. Michael P. MannsKlinik für Gastroenterologie,Hepatologie und EndokrinologieMedizinische Hochschule HannoverCarl-Neuberg-Str . 130625 HannoverGermanymanns .michael@mh-hannover .de

Prof. Dr. Patrick MarcellinHôpital BeaujonService d‘Hépatologie100, Bd . Général Leclerc92118 ClichyFrancepatrick .marcellin@bjn .ap-hop-paris .fr

Wajahat Z. Mehal, M.D., Ph.D.Associate Professor of MedicineYale School of MedicineYale Digestive DiseasesDana Building, 3rd Floor789 Howard AvenueNew Haven CT 06520USAwajahat .mehal@yale .edu

Dr. Phil Newsome, Ph.D.University of BirminghamThe Medical SchoolCenter for Liver Research5th FloorBirmingham B15 2TTGreat Britainp .n .newsome@bham .ac .uk

Dr. Stephen P. PereiraUniversity College HospitalMedical SchoolInstitute of Liver Studies250 Euston Rd .London NW1 2PGGreat Britainstephen .pereira@ucl .ac .uk

Prof. Dr. Thomas PietschmannAbteilung für Experimentelle VirologieTWINCOREZentrum für Experimentelle undKlinische Infektionsforschung GmbHFeodor-Lynen-Str . 730625 HannoverGermanythomas .pietschmann@twincore .de

Prof. Dr. Massimo Pinzani, Ph.D.Sheila Sherlock Chair of HepatologyUCL Institute for Liver andDigestive HealthRoyal Free Hospital U3Pond StreetLondon NW3 2QGGreat Britainm .pinzani@ulc .ac .uk

Prof. Dr. Raoul PouponHôpital Saint-AntoineService d‘Hépato-Gastro-Entérologie184, rue du Faubourg St . Antoine75571 ParisFranceraoul .poupon@gmail .com

Dr. Sheikh T. RashidUniversity of CambridgeAddenbrooke‘s HospitalDepartment of MedicineHills RoadCambridge CB2 OXYGreat Britainstr29@cam .ac .uk

Prof. Dr. Vlad RatziuHôpital Pitié SalpêtrièreService d‘hépatogastroentérologi47 - 83, boulevard de l‘Hopital75013 ParisFrancevratziu@teaser .fr

23

Dr. Helen ReevesNorthern Institute forCancer ResearchPaul‘O Gorman Bldg .Newcastle UniversityFramlington PlaceNewcastle-Upon-Tyne NE2 4HHGreat Britainh .l .reeves@ncl .ac .uk

Simon C. Robson, M.D., Ph.D.Professor of MedicineHarvard Medical SchoolDepartment of MedicineOffice E/CLS 6123 Blackfan Circle330 Brookline AveBoston MA02115USAsrobson@bidmc .harvard .edu

Prof. Dr. Alberto Sanchez-FueyoKing‘s College HospitalHead of Liver SciencesDenmark HillLondon SE5 9RSGreat Britainsanchez_fueyo@kcl .ac .uk

Dr. Meera ShahUniversity of CambridgeAddenbrooke‘s HospitalDepartment of MedicineBox 210, Hills RoadCambridge CB2 0QQGreat Britainmeerashah79@gmail .com

Prof. Dr. Howard C. ThomasSt . Mary’s HospitalMedical SchoolDepartment of MedicinePraed StreetLondon W2 1NYGreat Britainh .thomas@imperial .ac .uk

Prof. Dr. Mark R. ThurszSt . Mary‘s HospitalMedical SchoolImperial College London St .Marys Campus QEQMPraed StreetLondon W2 1NYGreat Britainm .thursz@imperial .ac .uk

Prof. Dr. Michael TraunerMedizinische Universität WienKlinische Abteilung fürGastroenterologie & HepatologieWähringer Gürtel 18-201090 WienAustriamichael .trauner@meduniwien .ac .at

Dr. Erica VillaPoliclinico di ModenaClinica Medica UniversitaVia del Pozzo, 7141100 ModenaItalyerica .villa@unimore .it

Prof. Dr. Arndt VogelKlinik für Gastroenterologie,Hepatologie und EndokrinologieMedizinische Hochschule HannoverCarl-Neuberg-Str . 130625 HannoverGermanyvogel .arndt@mh-hannover .de

Dr. Kate WilliamsonJohn Radcliffe HospitalNHS TrustGastroenterology DepartmentLevel 5Headley Way HeadingtonOxford OX3 9DUGreat Britainkate .williamson@ouh .nhs .uk

24

Congress OfficeDuring Falk Symposium 191

Telephone: +49 (0)175/7795327

Park Plaza Westminster Bridge200 Westminster Bridge RoadLondon SE1 7UTGreat Britain

Opening Hours:Thursday, October 3, 2013 7 .30 – 18 .00 hFriday, October 4, 2013 7 .30 – 18 .00 hSaturday, October 5, 2013 8 .00 – 17 .00 h

Congress FeesScientific program of Falk Symposium 191 e 200,–Students and residents e 100,–

* * * OR * * *

Day ticket e 120,–Students and residents e 60,–

Employees of pharmaceutical companiesand their guestsFalk Symposium 191 e 600,-

The congress fees include:- Refreshments during coffee breaks- Lunch on October 4 and 5, 2013- A copy of the abstract volume

25

Admission to Scientific EventsFor admission to scientific events your name badge should be clearly visible .

Congress ReportThe official congress report of the Falk Symposium 191 “Liver Diseases in 2013:Advances in Pathogenesis and Treatment” will be published in English in the first halfof 2014 by Karger, Switzerland . Orders for this book at a reduced subscription price ofe 35,- can be placed at the Congress Office during the congress in London .

Hotel AccommodationHotel reservations can be made online:http://www .visitlondon .com/where-to-stay

AirportLondon City Airport 13 km from the congress venueHeathrow Airport 30 km from the congress venueLondon Gatwick Airport 50 km from the congress venueLuton Airport 56 km from the congress venueStansted Airport London 65 km from the congress venueLondon Southend Airport 70 km from the congress venue

Innovative Drugsfor bowel and liver diseases

Modern formulations and specially designed delivery systemsensure targeted release of the active drug

Scientific Dialoguein the interest of therapeutic progress

Falk Symposia and Workshopsover 250 with almost 130,000 international participants since 1967

Continuing medical education seminarsover 15,500, attended by more than 1.2 million physicians and patients in Germany alone

Comprehensive literature service for healthcare professionals and patientswith more than 200 publications

www.falkfoundation.org www.drfalkpharma.comLeinenweberstr. 5 79108 Freiburg Germany Tel +49 (0)761/1514-0 Fax +49 (0)761/1514-321 Mail zentrale@drfalkpharma.de

General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49(0)761/1514-0Telefax: +49(0)761/1514-359E-mail: symposia@falkfoundation .dewww .falkfoundation .de

P191

e1-

9/2

013

/1 .3

00

Stü